Trial
NCT02034123
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Carcinoma, Small Cell
Intervention
GSK2879552
Why stopped
The risk benefit in relapsed refractory SCLC does not favor continuation of the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-06